Back to results
US 2014/0275199 A1Published application
Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
AssigneeBayer Intellectual Property GmbH
InventorsNingshu Liu, Kai Thede, Ursula Mönning, Arne Scholz, Christoph-Stephan Hilger, Ulf Bömer, Reiner Fischer
Life of this patent
Estimating the term…
Abstract
The invention relates to substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-ones, in particular for therapeutic purposes, to pharmaceutical compositions and to their use in therapy, in particular for the prophylaxis and therapy of neoplastic disorders.
Claims22
Compounds of the formula (I)
- in which
- R1 represents a trifluoromethyl or methoxymethyl group and
- R2 represents hydrogen or fluorine,
- and their salts.
1 more element
A compound selected from
- (5r,8r)-3-(4′-chloro-3′-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-8-(methoxymethyl)-1-azaspiro[4.5]dec-3-en-2-one;
- (5r,8r)-3-(4′-chloro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-8-(methoxymethyl)-1-azaspiro[4.5]dec-3-en-2-one;
- (5r,8r)-3-(4′-chloro-3′-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-8-(trifluoromethyl)-1-azaspiro[4.5]dec-3-en-2-one;
- and
- (5r,8r)-3-(4′-chloro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-8-(trifluoromethyl)-1-azaspiro[4.5]dec-3-en-2-one.
2 more elements
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.